BidaskClub Upgrades TG Therapeutics, Inc. (NASDAQ:TGTX) to “Sell”
TG Therapeutics, Inc. (NASDAQ:TGTX) was upgraded by research analysts at BidaskClub from a “strong sell” rating to a “sell” rating in a note issued to investors on Sunday.
A number of other equities research analysts have also issued reports on TGTX. FBR & Co reissued a “buy” rating on shares of TG Therapeutics in a research note on Saturday, June 17th. Zacks Investment Research raised TG Therapeutics from a “hold” rating to a “buy” rating and set a $12.00 target price for the company in a research report on Thursday. Jefferies Group LLC reaffirmed a “buy” rating and set a $23.00 target price on shares of TG Therapeutics in a research report on Monday, June 5th. Raymond James Financial, Inc. reaffirmed a “buy” rating on shares of TG Therapeutics in a research report on Friday, April 21st. Finally, ValuEngine raised TG Therapeutics from a “sell” rating to a “hold” rating in a research report on Friday, June 2nd. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and eleven have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $23.67.
Shares of TG Therapeutics (NASDAQ TGTX) traded up 1.40% during mid-day trading on Friday, reaching $10.85. The company’s stock had a trading volume of 1,111,744 shares. TG Therapeutics has a 52-week low of $4.10 and a 52-week high of $15.35. The company’s market cap is $668.97 million. The company has a 50-day moving average price of $11.64 and a 200 day moving average price of $8.75.
TG Therapeutics (NASDAQ:TGTX) last issued its quarterly earnings results on Friday, May 5th. The biopharmaceutical company reported ($0.52) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.42) by $0.10. TG Therapeutics had a negative return on equity of 135.31% and a negative net margin of 60,613.16%. The business had revenue of $0.04 million for the quarter, compared to the consensus estimate of $0.04 million. Equities analysts expect that TG Therapeutics will post ($1.79) earnings per share for the current year.
In other TG Therapeutics news, CFO Sean A. Power sold 59,976 shares of TG Therapeutics stock in a transaction on Monday, June 19th. The stock was sold at an average price of $11.09, for a total transaction of $665,133.84. Following the completion of the sale, the chief financial officer now directly owns 477,464 shares of the company’s stock, valued at approximately $5,295,075.76. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Insiders own 16.70% of the company’s stock.
A number of large investors have recently modified their holdings of the stock. FMR LLC raised its position in TG Therapeutics by 70.2% in the first quarter. FMR LLC now owns 6,451,713 shares of the biopharmaceutical company’s stock valued at $75,162,000 after buying an additional 2,660,949 shares during the last quarter. Vanguard Group Inc. raised its position in TG Therapeutics by 16.0% in the first quarter. Vanguard Group Inc. now owns 1,790,583 shares of the biopharmaceutical company’s stock valued at $20,860,000 after buying an additional 246,404 shares during the last quarter. Jennison Associates LLC bought a new position in TG Therapeutics during the first quarter valued at approximately $16,034,000. Columbus Circle Investors raised its position in TG Therapeutics by 29.3% in the first quarter. Columbus Circle Investors now owns 1,004,421 shares of the biopharmaceutical company’s stock valued at $11,702,000 after buying an additional 227,722 shares during the last quarter. Finally, State Street Corp raised its position in TG Therapeutics by 6.7% in the fourth quarter. State Street Corp now owns 679,115 shares of the biopharmaceutical company’s stock valued at $3,157,000 after buying an additional 42,760 shares during the last quarter. 46.27% of the stock is owned by institutional investors and hedge funds.
About TG Therapeutics
TG Therapeutics, Inc (TG) is a biopharmaceutical company focused on the acquisition, development and commercialization of treatments for B-cell malignancies and autoimmune diseases. As of December 31, 2016, the Company was developing two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a glycoengineered monoclonal antibody that targets a specific epitope on the cluster of differentiation (CD20) antigen found on mature B-lymphocytes.
Receive News & Ratings for TG Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.